Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07017699 · ClinicalTrials.gov registry record
A Study to Assess Deucravacitinib Safety in Pregnancy
A clinical trial of Psoriasis (PsO), sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- 900
- Enrollment target
- 1
- Study location
NCT07017699 is a study of Psoriasis (PsO) that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 900 participants, below the 1,018-participant average among 3 other Psoriasis (PsO) trials with a reported enrollment target (12% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07017699, a study of Psoriasis (PsO), is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- 900 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists \[OTIS\]) who were exposed to deucravacitinib.
Conditions Studied
Interventions
- DRUG Deucravacitinib
- DRUG Other systemic treatments for PsO
Study Locations (1)
California
- University of California San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2029-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07017699
The ClinicalTrials.gov registry entry for NCT07017699 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,018-participant average among 3 other Psoriasis (PsO) trials with a reported enrollment target (12% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis (PsO) appearing as the primary indexed condition, and to 2 interventions - of which Deucravacitinib is the first listed.
NCT07017699 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07017699 about?
NCT07017699 is a clinical study titled "A Study to Assess Deucravacitinib Safety in Pregnancy". The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists \[OTIS\]) who were exposed to deucravacitinib.
What is the current status of trial NCT07017699?
This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2025-03-21. Estimated completion is 2029-02-28.
What conditions does trial NCT07017699 study?
This clinical trial studies the following conditions: Psoriasis (PsO).
What interventions are being tested in trial NCT07017699?
The interventions under investigation include: Deucravacitinib (DRUG), Other systemic treatments for PsO (DRUG).
Who is sponsoring clinical trial NCT07017699?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07017699 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis (PsO)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
RECRUITING · Phase 1
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Trial of Academic Detailing to Promote Prescribing of Biosimilars
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.